On the other hand, the lack of association between TRX and parameters of glucose metabolism in CS patents, but not in healthy controls, could suggest that a compensatory increase in TRX may not be adequate to limit enhanced TXNIP activity in CS patients. This evidence concerns the gene TXNIP and Cowden syndrome 1.